Evidence map›Paper›PMID 32701678›Full record

ReviewCurrent opinion in pulmonary medicine2020

Molecular profiling in sarcoidosis.

Nicholas K Arger, Brian O'Connor, Laura L Koth

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in pulmonary medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Pathogenetic Mechanisms Linking Sarcoidosis to Lymphoma.International journal of molecular sciences · 2025
    Review
  2. Review
  3. Observational
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Nicholas K ArgerDivision of Pulmonary and Critical Care, University of California, San Francisco, San Francisco, California.
Brian O'ConnorNational Jewish Health, Center for Genes, Environment, & Health, Denver, Colorado, USA.
Laura L KothDivision of Pulmonary and Critical Care, University of California, San Francisco, San Francisco, California.
University of California, San Francisco · USNational Jewish Health · US

Funding

MUTIDISCIPLINARY TRAINING PROGRAM IN LUNG DISEASEST32HL007185 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI David J Erle, LAURENCE HUANG · 1985 to 2026
$24.6M
A Prospective Study of T cell Immune-phenotype and Disease Outcome in Pulmonary SarcoidosisR01HL136681 · NHLBI · NATIONAL JEWISH HEALTH · PI HAMZEH, NABEEL, KOTH, LAURA L · 2018 to 2021
$4.0M
Epigenetic Regulation of Altered T-cell Immunity in SarcoidosisR01HL127461 · NHLBI · NATIONAL JEWISH HEALTH · PI HAMZEH, NABEEL, O'CONNOR, BRIAN P · 2016 to 2019
$2.1M
Mentoring Research in Precision Medicine for Lung DiseaseK24HL137013 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PRESCOTT G WOODRUFF · 2017 to 2026
$1.2M
NHLBI NIH HHS K24 HL137013NHLBI NIH HHS R01 HL127461NHLBI NIH HHS T32 HL007185
6 · The paper itself

Abstract

purpose of reviewSarcoidosis is a systemic disease characterized by granulomatous inflammation of unknown cause. There is extensive heterogeneity between patients with respect to the number and types of organs involved, disease course, and response to therapy. Recent research in the field has leveraged 'omics' techniques such as transcriptomics to identify important 'molecular profiles' in the disease. These tools may help in identifying clinically useful biomarkers and targets for therapy. RECENT

findingsSeveral studies have used gene expression profiling of predesignated lists or the entire genome to find genes and markers that differentiate sarcoidosis from healthy controls, but only a few have compared sarcoidosis patients based on disease phenotypes and organ involvement. The common gene pathways that have been repeatedly identified include those related to the interferon response, T-cell receptor signaling, and the major histocompatibility complex. SUMMARY: While the molecular profiling studies to date offer the ability to compare sarcoidosis and health as well as across tissues, further longitudinal studies that include sarcoidosis patients with varying outcomes with respect to organ involvement and response to treatment are needed to identify clinically important phenotypes in the disease that can then be differentiated based on molecular features.

Indexed as

Gene Expression ProfilingBiomarkersDisease ProgressionGene Regulatory NetworksGenomicsHumansInterferon-gammaMetabolomicsMicrobiotaMicroRNAsPhenotypeProteomicsReceptors, Antigen, T-CellSarcoidosisSignal TransductionT-LymphocytesBiomarkersInterferon-gammaMicroRNAsReceptors, Antigen, T-Cell

Identifiers

PMID32701678
PMCPMC7899149
OpenAlexW3044491035

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.